• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Synova Healthcare Group, Inc. Partners With the Investor Relations Group of New York

Posted on: Wednesday, 31 May 2006, 09:01 CDT

Synova Healthcare Group, Inc. (OTC BB: SNVH), a developer of rapid, non-invasive, over-the-counter and point-of-care diagnostic tests, has contracted with The Investor Relations Group, Inc. ('IRG') of New York City to serve as its new financial relations and corporate communications company.

IRG will strive to increase investor awareness of Synova Healthcare Group, Inc. within the U.S. market by introducing the Company and its management to pre-qualified fund managers. In the future, U.S. investor inquiries relating to Synova Healthcare Group, Inc. can be directed to The Investor Relations Group, New York, NY, Telephone: (212) 825-3210, Fax (212) 825-3229.

Stephen King, Chairman and CEO of Synova Healthcare Group, Inc., said: "This is an exciting time for our Company. We believe there is a growing demand for rapid, non-invasive diagnostic tests that can streamline disease management and reduce health care costs. We are looking to increase the awareness of Synova Healthcare Group, Inc. by incorporating a more affirmative outreach program. We chose to partner with The Investor Relations Group because of its impressive track record of cultivating long-term relationships with premier fund managers and the media."

Synova Healthcare Group, Inc. develops and distributes both over-the-counter (OTC) and point-of-care (POC) diagnostic tests that allow consumers and healthcare professionals alike to rapidly and accurately diagnose and/or monitor the onset of specific medical conditions. The Company's existing product portfolio currently includes MenoCheck(R), MenocheckPro(R) and Fem-V(TM). MenoCheck(R) and Fem-V(TM) are rapid, over-the-counter, non-invasive, in-home diagnostic products: MenoCheck(R) is a urine FSH (Follicle-Stimulating Hormone) test for use in detecting and diagnosing the onset of menopause. Fem-V(TM) is an over-the-counter, non-invasive diagnostic test that resides within a unique pantiliner design and is useful for the diagnosis of vaginal infections. MenocheckPro(R) enables healthcare professionals to quickly and accurately determine whether their patients are transitioning into menopause in the clinical setting. Additional information can be found at www.synovahealthcare.com.

About The Investor Relations Group

The Investor Relations Group, Inc., (IRG) founded in 1996, represents select publicly traded companies, with a unique specialization for assisting those in the small-cap sector. IRG arranges one-on-one meetings for its portfolio companies with pre-qualified money managers handling investment portfolios that range from $10 million to $10 billion+ selected from its proprietary contact base of over 50,000 qualified fund managers who have an investing history in small cap stocks. IRG is a full-service corporate communications company offering services for its portfolio companies that include writing all press releases and shareholder communications and serving as primary contact for the investing community. IRG also houses a full-service public relations arm that specializes in building awareness of its companies within the financial and trade media, as well as the public at large. For further information, please visit the company's website at www.investorrelationsgroup.com.

This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates", "believes", "estimates", "expects", "plans", "intends", "potential" and similar expressions. These statements reflect the Company's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance or achievements to differ materially from those expressed in or implied by such statements. Such risk factors are discussed in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2005, as filed with the Securities and Exchange Commission on April 17, 2006, as well as in other periodic reports and filings with the Commission. There can be no assurance that such factors will not affect the accuracy of such forward-looking statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information set forth in this Press Release including such forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy; nor will there be any sale of securities of Synova Healthcare Group, Inc. in any state where such offer, solicitation or sale would be unlawful before registration or qualification under the securities laws of those states.

Source: Business Wire

More News in this Category